Clinical
RSSArticles
-
Diagnostic Concordance in Breast Biopsies
A comparison of breast biopsy diagnosis by clinical pathologists found a 75% concordance with a consensus-derived expert diagnostic interpretation. Concordance was lowest with the diagnosis of atypical, with under-diagnosis noted in 35% of cases.
-
Intrauterine Insemination Outcomes Are Not Affected by Sperm Morphology Parameters
Pregnancy rates following intrauterine insemination are not affected by abnormalities of sperm morphology.
-
Using Etonogestrel Implants and LNG-IUDs Past FDA-approved Duration
In this small prospective cohort study, use of the etonogestrel implant and the levonorgestrel intrauterine device for an additional year past their FDA-approved duration was associated with an acceptably low failure rate.
-
OnabotulinumtoxinA and the Bladder
ABSTRACT & COMMENTARY: Healthcare providers should thoroughly counsel patients on the risks associated with onabotulinumtoxinA toxin injections.
-
Nurses text, send images from the OR with new app
Arnold Palmer Hospital for Children in Orlando, FL, uses a new app that feeds information from the operating room directly to the smartphones of a patient’s family and loved ones. It’s called EASE, which stands for Electronic Access to Surgical Events.
-
Study: Minimally invasive surgery could lower healthcare costs by hundreds of millions a year
A new analysis of surgical outcomes nationwide concludes that more use of minimally invasive surgery for certain common procedures can dramatically reduce postoperative complications and shave hundreds of millions of dollars off the nation’s healthcare bill.
-
One year after surgery, preoperative program to quit smoking still shows benefits
Patients receiving a brief intervention to help them quit smoking before surgery are more likely to be nonsmokers at one-year follow-up, reports a study in Anesthesia & Analgesia.
-
Can you offer total hips and knees in 23 hours? Yes!
Start posting patients for hip replacements and send them home in less than 24 hours directly from your surgery center. No 72-hour-stay facility is needed.
-
FDA Greenlights Biosimilars
In one of the most important decisions of the past 5 years, the FDA has given the greenlight to the first biosimilar drug with the approval of Sandoz’s filgrastim-sndz, a copy of Amgen’s multibillion dollar drug filgrastim (Neupogen). Biosimilars are drugs that are derived from living organisms and thus cannot be exact copies of the original compounds. They are different from generics in this respect. But the FDA has agreed to approve biologic copies that are “highly similar to another, already FDA-approved biologic (known as the reference product).”
-
Might Long-term Dual Antiplatelet Therapy Be Better? Not
Risk reduction provided by dual antiplatelet therapy (DAT) in the short-term interval (3-12 months) after coronary stenting is well established, and published guidelines provide consistent advice about appropriate duration of such therapy.